These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31206775)

  • 1. Marginal hazard ratio estimates in joint frailty models for heart failure trials.
    Toenges G; Jahn-Eimermacher A
    Biom J; 2019 Nov; 61(6):1385-1401. PubMed ID: 31206775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model.
    Rogers JK; Yaroshinsky A; Pocock SJ; Stokar D; Pogoda J
    Stat Med; 2016 Jun; 35(13):2195-205. PubMed ID: 26751714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational issues in fitting joint frailty models for recurrent events with an associated terminal event.
    Toenges G; Jahn-Eimermacher A
    Comput Methods Programs Biomed; 2020 May; 188():105259. PubMed ID: 31862679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
    Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A joint frailty model to estimate the recurrence process and the disease-specific mortality process without needing the cause of death.
    Belot A; Rondeau V; Remontet L; Giorgi R;
    Stat Med; 2014 Aug; 33(18):3147-66. PubMed ID: 24639014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved.
    Rogers JK; Pocock SJ; McMurray JJ; Granger CB; Michelson EL; Östergren J; Pfeffer MA; Solomon SD; Swedberg K; Yusuf S
    Eur J Heart Fail; 2014 Jan; 16(1):33-40. PubMed ID: 24453096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of semiparametric approaches to evaluate composite endpoints in heart failure trials.
    Toenges G; Mütze T; Jahn-Eimermacher A
    Stat Med; 2021 Nov; 40(26):5702-5724. PubMed ID: 34327735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A positive stable frailty model for clustered failure time data with covariate-dependent frailty.
    Liu D; Kalbfleisch JD; Schaubel DE
    Biometrics; 2011 Mar; 67(1):8-17. PubMed ID: 20528861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Solomon SD; Wang D; Finn P; Skali H; Zornoff L; McMurray JJ; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pocock S; Pfeffer MA
    Circulation; 2004 Oct; 110(15):2180-3. PubMed ID: 15466644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
    Solomon SD; Dobson J; Pocock S; Skali H; McMurray JJ; Granger CB; Yusuf S; Swedberg K; Young JB; Michelson EL; Pfeffer MA;
    Circulation; 2007 Sep; 116(13):1482-7. PubMed ID: 17724259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    McMurray JJ; Andersson FL; Stewart S; Svensson K; Solal AC; Dietz R; Vanhaecke J; van Veldhuisen DJ; Ostergren J; Granger CB; Yusuf S; Pfeffer MA; Swedberg K
    Eur Heart J; 2006 Jun; 27(12):1447-58. PubMed ID: 16754631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of statistical methods for the analysis of recurrent adverse events in the presence of non-proportional hazards and unobserved heterogeneity: a simulation study.
    Patson N; Mukaka M; Kazembe L; Eijkemans MJC; Mathanga D; Laufer MK; Chirwa T
    BMC Med Res Methodol; 2022 Jan; 22(1):24. PubMed ID: 35057743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.
    Felker GM; Allen LA; Pocock SJ; Shaw LK; McMurray JJ; Pfeffer MA; Swedberg K; Wang D; Yusuf S; Michelson EL; Granger CB;
    J Am Coll Cardiol; 2007 Jul; 50(1):40-7. PubMed ID: 17601544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
    Demers C; McMurray JJ; Swedberg K; Pfeffer MA; Granger CB; Olofsson B; McKelvie RS; Ostergren J; Michelson EL; Johansson PA; Wang D; Yusuf S;
    JAMA; 2005 Oct; 294(14):1794-8. PubMed ID: 16219883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Kenchaiah S; Pocock SJ; Wang D; Finn PV; Zornoff LA; Skali H; Pfeffer MA; Yusuf S; Swedberg K; Michelson EL; Granger CB; McMurray JJ; Solomon SD;
    Circulation; 2007 Aug; 116(6):627-36. PubMed ID: 17638930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A flexible class of generalized joint frailty models for the analysis of survival endpoints.
    Chauvet J; Rondeau V
    Stat Med; 2023 Apr; 42(8):1233-1262. PubMed ID: 36775273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
    Pocock SJ; McMurray JJ; Dobson J; Yusuf S; Granger CB; Michelson EL; Ostergren J; Pfeffer MA; Solomon SD; Anker SD; Swedberg KB
    Eur Heart J; 2008 Nov; 29(21):2641-50. PubMed ID: 18819960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On robustness of marginal regression coefficient estimates and hazard functions in multivariate survival analysis of family data when the frailty distribution is mis-specified.
    Hsu L; Gorfine M; Malone K
    Stat Med; 2007 Nov; 26(25):4657-78. PubMed ID: 17348081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial.
    Kotalik A; Eaton A; Lian Q; Serrano C; Connett J; Neaton JD
    Clin Trials; 2019 Dec; 16(6):626-634. PubMed ID: 31389723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.